Grifols GRFS
NASDAQ GRFS
$8.00 +0.01 (+0.13%)
At close: Aug 21, 2026 · 4:00 PM EDT

Grifols (GRFS) Income from Continuing Operations (2010 - 2020)

Grifols' (GRFS) quarterly Income from Continuing Operations came in at 330091015.77 in Q1 2020, up 69.41% YoY from 194843192.77 in Q2 2019, and down 55.46% on a QoQ basis from 741176413.24 in Q4 2019.

Grifols (GRFS) Income from Continuing Operations (2010 - 2020) Analysis & Trends

Grifols (GRFS) has 11 years of Income from Continuing Operations data on file, last reported at 330091015.77 in Q1 2020.

  • Quarterly Income from Continuing Operations rose 69.41% year-over-year to 330091015.77 in Q1 2020, while the trailing twelve-month figure through Mar 2020 was 2068492905.63 (up 35.91% YoY) and the FY2025 annual result came in at 582021757.35, up 155.71% from the prior year.
  • Income from Continuing Operations eased to 330091015.77 in Q1 2020, from 741176413.24 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 882309060.91 in Q4 2017 to a low of 285025600.06 in Q4 2016.
  • A 5-year average of 346580489.46 and a median of 260548010.52 in 2018 frame the typical range for Income from Continuing Operations.
  • Annual changes were most pronounced in 2016 — Income from Continuing Operations tumbled 269.94% — and 2017, when it jumped 409.55%.
  • Tracing GRFS's Income from Continuing Operations over 5 years: stood at 285025600.06 in 2016, then surged by 409.55% to 882309060.91 in 2017, then declined by 9.06% to 802382283.85 in 2018, then fell by 7.63% to 741176413.24 in 2019, then slumped by 55.46% to 330091015.77 in 2020.
  • The last three Income from Continuing Operations figures came in at 330091015.77 (Q1 2020), 741176413.24 (Q4 2019), and 194843192.77 (Q1 2019), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn 5.53 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn 3.62 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn -1.34 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn 3.26 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn 2.51 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn 2.38 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn -10.50 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn -246.00 Mn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn 207.96 Mn
10 Grifols 5.45 Bn 4.45 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2020 330.09 Mn
Dec 31, 2019 741.18 Mn
Mar 31, 2019 194.84 Mn
Dec 31, 2018 802.38 Mn
Jun 30, 2018 260.55 Mn
Mar 31, 2018 264.14 Mn
Dec 31, 2017 882.31 Mn
Jun 30, 2017 255.10 Mn
Mar 31, 2017 247.88 Mn
Dec 31, 2016 -285.03 Mn
Sep 30, 2016 227.94 Mn
Jun 30, 2016 202.82 Mn
Mar 31, 2016 381.34 Mn
Dec 31, 2015 -77.05 Mn
Sep 30, 2015 227.51 Mn
Jun 30, 2015 215.29 Mn
Mar 31, 2015 305.44 Mn
Dec 31, 2014 -531.60 Mn
Sep 30, 2014 180.98 Mn
Jun 30, 2014 141,763.74